Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study

Inclusion Criteria: * Legal at the time of signing the agreement * Subject affiliated to the french social protection * Ileostomy has achieved since 10 days minimum at day 0 (D0: start of study treatment) * Ileostomy output \> 1.5 liters / 24h for at least 24 hours at day 0 * accept to use an effective method of contraception during the study: (during the 6 months following injection of lanreotide for the experimental group and for the control group: 4 days after the last dose of chlorhydrate of loperamide * People able to understand the objectives, modalities and risks related to the study and give written informed consent Exclusion Criteria: * people with guardianship or with judicial protection * simultaneous participation in another biomedical research protocol involving a drug or topic exclusion period * pregnancy or breastfeeding * administration of lanreotide or related peptide between surgery and D0 * hypersensitivities to lanreotide or related peptides and / or diosmectite and / or loperamide and / or one of their excipients * acute hemorrhagic colitis * bloody diarrhea and / or high fever * Clostridium Difficile Infection at the inclusion * uncontrolled diabetis defined by HbA1c\> 7% at D0